(PRWEB) May 21, 2017 -- Scientists in Chengdu, China have released the results of a meta-analysis on the prognostic value of soluble mesothelin-related protein, a protein found in higher amounts in people with malignant mesothelioma. Surviving Mesothelioma has the details. Click here to read the article now.
Researchers at Sichuan University used eight studies including 579 mesothelioma patients to compare mesothelioma survival times to patients’ SMRP levels.
“The results showed that soluble mesothelin level was significantly correlated with the survival of malignant pleural mesothelioma,” writes lead author Dr. Long Tian.
The analysis in the journal Oncotarget suggests that survival was also significantly correlated with mesothelioma histological subtype and cancer stage.
“There are many studies on the use of SMRP in diagnosing mesothelioma and determining treatment response,” says Alex Strauss, Managing Editor for Surviving Mesothelioma. “This study is significant because it focuses on the potential role for this protein in mesothelioma prognosis, which can be critical for treatment planning.”
To learn more about SMRP and its potential as a prognostic indicator for malignant mesothelioma, see Predicting Mesothelioma Outcomes with Soluble Mesothelin, now available on the Surviving Mesothelioma website.
Tian, L, et al, “Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis”, April 26, 2017, Oncotarget, Epub ahead of print, https://www.ncbi.nlm.nih.gov/pubmed/28507279
For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.
Michael Ellis, Cancer Monthy, http://www.survivingmesothelioma.com, +1 (919) 570-8595, [email protected]
Share this article